The Cancer Letter

Inside information on cancer research and drug development

Cancer History ProjectConversation with The Cancer Letter

Viral oncology’s complicated path—from cancer as contagion to today’s immunotherapy

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

In the late 1960s, NCI received the modern-day equivalent of billions of dollars to establish a viral oncology program.  At the time, the study of the role viruses played in cancer (or whether they played any role at all) was unknown.  This could have been either a triumph or a huge and embarrassing waste of...

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Alexandria Carolan
Alexandria Carolan
Reporter
Table of Contents

YOU MAY BE INTERESTED IN

Conversation with The Cancer Letter

Infections are a major cause of death in patients treated with CAR T-cell therapy
Meta-analysis focused on causes of death, excluding relapse, recurrence

More than half of deaths that are not attributed to disease progression or recurrence after CAR T-cell therapy are caused by infections—an unprecedented finding that experts say marks a shift from a conventional focus on mitigating treatment-specific adverse events to including prevention and management of infections.
By Matthew Bin Han Ong
Byline
Alexandria Carolan
Alexandria Carolan
Reporter
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account